Exploratory, non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFRß) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 15
• 2 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults and adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). It studies how a PET scan tracer called 68Ga-ATH001 binds in the lungs.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD), and healthy participants for comparison. The record gives no stage or severity.

Read by machine on 9 Nov 2026.

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details